Form 8-K - Current report:
SEC Accession No. 0001104659-20-011650
Filing Date
2020-02-06
Accepted
2020-02-06 09:06:27
Documents
7
Period of Report
2020-02-06
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm206940-1_8k.htm 8-K 28618
2 EXHIBIT 1.1 tm206940d1_ex1-1.htm EX-1.1 191082
3 EXHIBIT 4.1 tm206940d1_ex4-1.htm EX-4.1 124501
4 EXHIBIT 4.2 tm206940d1_ex4-2.htm EX-4.2 114293
5 EXHIBIT 5.1 tm206940d1_ex5-1.htm EX-5.1 11870
6 EXHIBIT 10.1 tm206940d1_ex10-1.htm EX-10.1 65778
7 GRAPHIC tm206940-1_8kimg01.jpg GRAPHIC 4183
  Complete submission text file 0001104659-20-011650.txt   543223
Mailing Address 5300 MEMORIAL DRIVE SUITE 950 HOUSTON TX 77007
Business Address 5300 MEMORIAL DRIVE SUITE 950 HOUSTON TX 77007 713-300-5160
Moleculin Biotech, Inc. (Filer) CIK: 0001659617 (see all company filings)

EIN.: 474671999 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37758 | Film No.: 20581156
SIC: 2834 Pharmaceutical Preparations